7 recruiting, 1 active not recruiting, 1 completed. 9 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 7, Active not recruiting 1, Completed 1 |
| Phase 1 | 5 | Recruiting 3, Active not recruiting 1, Completed 1 |
Follow SX-682: new trials by email Literature Review of SX-682 trials Research Report on SX-682
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-11-03 | 2026-10-29 |
| SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer Atezolizumab, CXCR1/2 Inhibitor SX-682, Biospecimen Collection - Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | University of Washington | 32 | 2026-10-06 | 2026-10-13 |
| Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer SX-682, Apalutamide - Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 78 | 2025-04-28 | 2026-09-08 |
| Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer SX-682, Enzalutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Syntrix Biosystems, Inc. | 53 | 2024-11-18 | 2026-06-02 |
| Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) Retifanlimab, Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform, N-803 - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 60 | 2024-03-26 | 2026-10-16 |
| A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer Tislelizumab, SX-682 - Pancreatic Cancer | Phase 2 | Recruiting | Lei Zheng | 25 | 2023-11-08 | 2026-10-07 |
| SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | University of Washington | 30 | 2023-04-06 | 2026-06-17 |
| Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) SX-682, M7824, MVA-BN-CV301 - Metastatic Cancer, Solid Tumors | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2020-11-24 | 2025-02-03 |
| SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial CXCR1/2 Inhibitor SX-682, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 51 | 2020-10-14 | 2026-07-20 |
Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Lung Neoplasms (2) · Prostatic Neoplasms (2) · Adenocarcinoma (1) · Carcinoma (1) · Carcinoma, Adenoid Cystic (1) · Colonic Neoplasms (1) · Head and Neck Neoplasms (1) · Hypopharyngeal Neoplasms (1) · Laryngeal Neoplasms (1) · Nasopharyngeal Carcinoma (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Paranasal Sinus Neoplasms (1)
National Cancer Institute (NCI) (3) · University of Washington (2) · Institute of Cancer Research, United Kingdom (1) · Lei Zheng (1) · M.D. Anderson Cancer Center (1) · Syntrix Biosystems, Inc. (1)
United States (8) · Switzerland (1) · United Kingdom (1)
Alisha Bent, MD (1) · Charalampos Floudas, M.D. (1) · Christina Baik, MD, MPH (1) · Christina S. Baik (1) · James L Gulley, M.D. (1) · Lei Zheng, MD (1) · Nicholas P Tschernia, M.D. (1) · Professor Johann de Bono, MB ChB, FRCP, MSc, PhD, FMedSc (1) · Syntrix Biosystems (1)
P50CA228944 (2), R44CA278187 (1)